Abstract
Imatinib, a selective tyrosine kinases inhibitor (TKI), has excellent efficacy in the treatment of chronic myeloid leukemia (CML). Imatinib resistance and intolerance opened the way to the development of second generation TKIs against CML, including nilotinib and dasatinib. Because all TKIs are more effective drugs in comparison with previous therapies in CML, the followup period is now longer in the TKI era. These compounds are prescribed for prolonged periods, often in patients with comorbidities. Therefore, monitoring of CML should comprise the response to TKIs and long term effects of the TKIs.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
